Skip to main content
POOLBEG PHARMA PLC logo

POOLBEG PHARMA PLC — Investor Relations & Filings

Ticker · POLB ISIN · GB00BKPG7Z60 LEI · 213800UZ8WJLWYHBFL52 IL Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country GB United Kingdom
Listing IL POLB

About POOLBEG PHARMA PLC

https://poolbegpharma.com/

Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company that develops and commercializes medicines for diseases with high unmet medical needs. The company's lead asset, POLB 001, is a treatment designed to prevent Cytokine Release Syndrome (CRS), a severe side effect associated with cancer immunotherapies, with the aim of making these treatments safer and more accessible. Poolbeg is also advancing an oral GLP-1 program for obesity, offering a patient-friendly therapeutic option. The company utilizes an artificial intelligence (AI)-led discovery platform that analyzes data from human challenge trials to identify novel drug targets. This AI-driven approach aims to accelerate target identification, reduce costs, and lower development risks.

Recent filings

Filing Released Lang Actions
POLB 001 poster to be presented at EHA 2026
Regulatory Filings Classification · 90% confidence The document is an RNS press release announcing Poolbeg Pharma’s presentation of a scientific poster at a medical congress (EHA 2026). It does not contain financial results, regulatory certifications, management changes, dividends, or detailed report data. It is a general regulatory announcement distributed via RNS and thus falls under the fallback category for miscellaneous regulatory filings.
2026-05-13 English
POLB 001 CRS patent granted in Canada
Regulatory Filings Classification · 92% confidence The document is an RNS announcement from Poolbeg Pharma plc concerning the grant of a Canadian patent for its POLB 001 cancer immunotherapy-induced CRS treatment. It is a press release/regulatory bulletin and not a financial report, meeting announcement, management change, or any other specified report type. It falls under general regulatory filings.
2026-05-11 English
Annual Report & AGM Notice
Report Publication Announcement Classification · 95% confidence The document is an announcement from Poolbeg Pharma plc dated 7 May 2026. It states that the Company's Annual Report and Accounts for the period ended 31 December 2025 and the notice of the Annual General Meeting (AGM) will be posted to shareholders today. It also mentions that these documents will shortly be available to download from the company's website. The text does not contain the actual Annual Report or financial statements but rather informs about the availability and posting of these reports and the AGM notice. The document length is 7722 characters, which is relatively short and consistent with an announcement rather than the full report. Therefore, according to the "Menu vs Meal" rule, this document is a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself.
2026-05-07 English
Results for the year ended 31 December 2025
Annual Report Classification · 92% confidence The document is an RNS regulatory announcement titled “Results for the year ended 31 December 2025” and includes audited full‐year results, detailed narrative statements by the CEO and Executive Chair, highlights of operational and financial performance, pipeline updates, patented grants, and the beginning of the annual report and financial statements. The length (~48,000 characters) and depth (including Chair’s statement, financial positions, operational review) indicate this is the full annual report rather than a brief earnings release or preview announcement. Therefore, it should be classified as an Annual Report (10-K). FY 2025
2026-04-28 English
Significant milestone for Poolbeg's IP portfolio
Regulatory Filings Classification · 92% confidence The document is an RNS announcement from Poolbeg Pharma plc regarding the grant of a patent by IP Australia. It is not a financial report, earnings release, AGM material, management change, or share transaction. It does not attach a full report, nor does it fit any specific category like M&A, dividends, or director dealings. Therefore it falls under a general regulatory announcement category (RNS).
2026-03-31 English
Appointment of Dr Adrian Kilcoyne to SAB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the appointment of a new member to the Scientific Advisory Board of Poolbeg Pharma. This falls under the category of management or board-level personnel changes. While it is distributed via RNS, it is a substantive announcement of a corporate appointment rather than a mere report publication notice or a general regulatory filing.
2026-03-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.